A single dose of respiratory syncytial virus vaccine was effective against infections and associated hospitalizations in veterans aged at least 60 years during the 2023-24 season.

The bivalent respiratory syncytial virus prefusion F vaccine is highly effective and well tolerated against RSV-associated ...

GSK's vaccine against respiratory syncytial ... GSK revealed the results from its pivotal AReSVi-006 trial of the RSV shot - called RSVPreF3 OA - having said earlier this year that the study ...

An Australian-first study demonstrating the effectiveness of a new immunization against respiratory syncytial virus (RSV) for ...

GSK to showcase latest research at the International RSV Symposium to advance RSV prevention in adults: London, UK Saturday, March 8, 2025, 14:00 Hrs [IST] GSK plc will share its ...

The World Health Organization (WHO) has announced that it has added Pfizer’s maternal respiratory syncytial virus (RSV) vaccine to its list of prequalified vaccines. Abrysvo, which is now the first ...

Population-based analyses of new vaccination programmes provide robust real-world evidence for post-licensure vaccine ...

The rollout of a vaccine for respiratory syncytial virus (RSV) has slashed hospital admissions by 30% among older people, according to early data. The benefits are likely to increase as more ...

PRC vaccine leader AIM Vaccine (06660.HK) announced on February 26 that its self-developed mRNA RSV (Respiratory Syncytial Virus) vaccine has recently received clinical trial approval from the U.S ...